Provided by Tiger Trade Technology Pte. Ltd.

Zentalis Pharmaceuticals, LLC

2.42
-0.1000-3.97%
Post-market: 2.29-0.1345-5.56%19:04 EST
Volume:1.33M
Turnover:3.27M
Market Cap:174.85M
PE:-1.16
High:2.62
Open:2.51
Low:2.40
Close:2.52
52wk High:3.95
52wk Low:1.01
Shares:72.25M
Float Shares:66.79M
Volume Ratio:3.94
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0805
EPS(LYR):-2.3331
ROE:-49.18%
ROA:-24.51%
PB:0.69
PE(LYR):-1.04

Loading ...

Zentalis Pharmaceuticals PAO and PFO Vincent Vultaggio Reports Disposal of Common Shares

Reuters
·
Feb 11

Vincent Vultaggio, PAO and PFO, Reports Sale of Zentalis Pharmaceuticals Common Shares

Reuters
·
Feb 05

Zentalis Pharmaceuticals to Participate in Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 04

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM

Reuters
·
Jan 12

Does Zentalis (ZNTL) Pairing DENALI Progress With Insider Buying Reveal a Shifting Oncology Strategy?

Simply Wall St.
·
Jan 11

Stocks to Watch: Bark, Zentalis Pharmaceuticals

Dow Jones
·
Jan 10

Walters Group Reports Acquisition of Common Shares of Zentalis Pharmaceuticals Inc

Reuters
·
Jan 09

BRIEF-Zentalis Pharmaceuticals Provides Corporate Update

Reuters
·
Jan 06

Zentalis Pharmaceuticals Announces Key 2026 Milestones for Azenosertib Development Program

Reuters
·
Jan 06

Zentalis Pharmaceuticals Inc - Denali Part 2a Enrollment Completed; Dose Confirmation Expected 1H 2026

THOMSON REUTERS
·
Jan 06

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

THOMSON REUTERS
·
Jan 06

Zentalis Pharmaceuticals Inc - Aspenova Phase 3 Trial Initiation Planned in 1H 2026

THOMSON REUTERS
·
Jan 06

Zentalis Pharmaceuticals Inc - Denali Part 2 Topline Readout Expected by Year End 2026

THOMSON REUTERS
·
Jan 06

Matrix Capital Management Company LP Reports Disposal of Zentalis Pharmaceuticals Common Shares

Reuters
·
Dec 16, 2025

Zentalis Pharmaceuticals Inc - Enters Stock Purchase Agreement With Matrix - SEC Filing

THOMSON REUTERS
·
Dec 16, 2025

Zentalis Pharmaceuticals Director Karan Takhar Resigns

Reuters
·
Dec 16, 2025

Zentalis Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Nov 13, 2025

Zentalis price target lowered to $4 from $8 at Morgan Stanley

TIPRANKS
·
Nov 11, 2025

Wedbush Remains a Hold on Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
Nov 11, 2025

Zentalis Pharmaceuticals (ZNTL) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Nov 11, 2025